FDA Permits Last-Resort Iclusig Use After Clinical Trial Deaths

Law360, New York (December 20, 2013, 7:04 PM EST) -- Two months after announcing a spate of deaths, the U.S. Food and Drug Administration on Friday allowed Ariad Pharmaceuticals Inc. to resume sales of leukemia drug Iclusig to a narrower universe of patients who will receive stronger warnings about the product’s serious risks.

The return comes after at least 14 people died while taking Iclusig in clinical trials that were intended to get a fuller picture of the drug’s safety and effectiveness after it received fast-track approval last year to treat two rare types of leukemia. The...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.